Quest Diagnostics Q3 revenue $3.10B up 10%; adjusted EPS $3.00 up 15.4%; raises FY2026 guidance

QUEST DIAGNOSTICS INC

Q3 net revenues $3.097B vs $2.816B; Diagnostic Information Services revenue $3.035B, up 10.2% YoY.
Requisition volume rose 14.5% (organic +14.4%) while revenue per requisition fell 4.2%; reported diluted EPS $2.78, up 28.7%.
Operating income $479M (15.5% of revenue); adjusted operating income $517M (16.7%); net income attributable to Quest $312M, up 27.6%.
FY2026 guidance raised: revenue $12.065-$12.105B (prior $11.95-$12.05B), adjusted diluted EPS $11.25-$11.35 (prior $11.05-$11.25), operating cash flow ~$1.90B.
Announced Quest lab panel with 50+ biomarkers sold via Apple Health app, definitive deal for Northeastern health system outreach lab assets, and AD-Detect pTau217 test launch.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.